Structural requirements within protoporphyrin IX in the inhibition of heat shock protein 90

Chemico-Biological Interactions

Volumn 204, Issue 1, 2013, Pages 49-57

  Lee, Woo Hyung ^a   Lee, Jung Min ^a   Lim, Chaemin ^a   Kim, Sanghee ^a   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

Author keywords

Angiogenesis; HIF 1 ; HSP90; Molecular modeling; PPIX

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOLEVULINIC ACID; BILIRUBIN; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PORPHINE; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; STERCOBILIN; UNCLASSIFIED DRUG; UROPORPHYRIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; COMPUTER MODEL; CONTROLLED STUDY; COW; DRUG STRUCTURE; IN VITRO STUDY; MALE; MOLECULAR DOCKING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RAT; TUMOR VASCULARIZATION; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELLS, CULTURED; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; MODELS, MOLECULAR; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTOPORPHYRINS;

EID: 84877866207     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2013.04.006     Document Type: Article

References (40)

1. M. Taipale, D.F. Jarosz, and S.L. Lindquist HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 7 2010 515 528
2. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat. Rev. Cancer 10 2005 761 772
3. X. Song, X. Wang, W. Zhuo, H. Shi, D. Feng, Y. Sun, Y. Liang, Y. Fu, D. Zhou, and Y. Luo The regulatory mechanism of extracellular Hsp90α on matrix metalloproteinase-2 processing and tumor angiogenesis J. Biol. Chem. 285 2010 40039 40049
4. N.J. Mabjeesh, D.E. Post, M.T. Willard, B. Kaur, E.G. Van Meir, J.W. Simons, and H. Zhong Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells Cancer Res. 62 2002 2478 2482
5. F. Koga, K. Kihara, and L. Neckers Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90 Anticancer Res. 29 2009 797 807
6. S.H. Oh, J.K. Woo, Y.D. Yazici, J.N. Myers, W.Y. Kim, Q. Jin, S.S. Hong, H.J. Park, Y.G. Suh, K.W. Kim, W.K. Hong, and H.Y. Lee Structural basis for depletion of heat shock protein 90 client proteins by deguelin J. Natl. Cancer Inst. 99 2007 949 961
7. S.Z. Usmani, R. Bona, and Z. Li 17 AAG for HSP90 inhibition in cancer-from bench to bedside Curr. Mol. Med. 9 2009 654 664
8. A.E. O'Connor, W.M. Gallagher, and A.T. Byrne Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy Photochem. Photobiol. 85 2009 1053 1074
9. M.W. Reed, F.N. Miller, T.J. Wieman, M.T. Tseng, and C.G. Pietsch The effect of photodynamic therapy on the microcirculation J. Surg. Res. 45 1988 452 459
10. U.O. Nseyo, J. DeHaven, T.J. Dougherty, W.R. Potter, D.L. Merrill, S.L. Lundahl, and D.L. Lamm Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience J. Clin. Laser Med. Surg. 16 1998 61 68
11. J.M. Lee, W.H. Lee, H.Y. Kay, E.S. Kim, A. Moon, and S.G. Kim Hemin, an iron-binding porphyrin, inhibits HIF-1alpha induction through its binding with heat shock protein 90 Int. J. Cancer 130 2012 716 727
12. M.K. Cho, W.D. Kim, S.H. Ki, J.I. Hwang, S. Choi, C.H. Lee, and S.G. Kim Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor Mol. Cell. Biol. 27 2007 6195 6208
13. L. Sahlin, Y. Stjernholm-Vladic, N. Roos, B. Masironi, and G. Ekman-Ordeberg Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming Reprod. Biol. Endocrinol. 6 2008 6
14. J.K. Min, Y.L. Cho, J.H. Choi, Y. Kim, J.H. Kim, Y.S. Yu, J. Rho, N. Mochizuki, Y.M. Kim, G.T. Oh, and Y.G. Kwon Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice Blood 109 2007 1495 1502
15. S. Ehrmantraut, M.W. Laschke, D. Merkel, C. Scheuer, V. Willnecker, A. Meyer-Lindenberg, M.D. Menger, and A. Naumann Perioperative steroid administration inhibits angiogenic host tissue response to porous polyethylene (Medpor) implants Eur. Cell Mater. 19 2010 107 116
16. J. Koska, V.Z. Spassov, A.J. Maynard, L. Yan, N. Austin, P.K. Flook, and C.M. Venkatachalam Fully automated molecular mechanics based induced fit protein-ligand docking method J. Chem. Inf. Model. 48 2008 1965 1973
17. B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, and M. Karplus CHARMM: a program for macromolecular energy minimization and dynamics calculations J. Comp. Chem. 4 1983 187 217
18. J. Tirado-Rives, and W.L. Jorgensen Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding J. Med. Chem. 49 2006 5880 5884
19. Y.V. Liu, and G.L. Semenza RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization Cell Cycle 6 2007 656 659
20. G.L. Semenza Hypoxia-inducible factor 1 (HIF-1) pathway Sci. STKE 407 2007 cm8
21. B.K. Eustace, T. Sakurai, J.K. Stewart, D. Yimlamai, C. Unger, C. Zehetmeier, B. Lain, C. Torella, S.W. Henning, G. Beste, B.T. Scroggins, L. Neckers, L.L. Ilag, and D.G. Jay Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness Nat. Cell Biol. 6 2004 507 514
22. E. Zelzer, Y. Levy, C. Kahana, B.Z. Shilo, M. Rubinstein, and B. Cohen Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT EMBO J. 17 1998 5085 5094
23. M.C. Brahimi-Horn, and J. Pouysségur Harnessing the hypoxia-inducible factor in cancer and ischemic disease Biochem. Pharmacol. 73 2007 450 457
24. Q. Ke, and M. Costa Hypoxia-inducible factor-1 (HIF-1) Mol. Pharmacol. 70 2006 1469 1480
25. G.L. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 29 2010 625 634
26. M. Sgobba, and G. Rastelli Structure-based and in silico design of Hsp90 inhibitors Chem. Med. Chem. 4 2009 1399 1409
27. L.H. Pearl, and C. Prodromou Structure, function, and mechanism of the Hsp90 molecular chaperone Adv. Protein Chem. 59 2001 157 186
28. I. Shachar, S. Cohen, A. Marom, and S. Becker-Herman Regulation of CLL survival by hypoxia-inducible factor and its target genes FEBS Lett. 586 2012 2906 2910
29. V.E. Belozerov, and E.G. Van Meir Hypoxia inducible factor-1: a novel target for cancer therapy Anticancer Drugs 16 2005 901 909
30. P.P. Hsu, and D.M. Sabatini Cancer cell metabolism: Warburg and beyond Cell 134 2008 703 707
31. A. Amirkhosravi, S.A. Mousa, M. Amaya, T. Meyer, M. Davila, T. Robson, and J.L. Francis Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis Methods Mol. Biol. 663 2010 241 259
32. C. Branco-Price, N. Zhang, M. Schnelle, C. Evans, D.M. Katschinski, D. Liao, L. Ellies, and R.S. Johnson Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success Cancer Cell 21 2012 52 65
33. T.E. Walshe, and P.A. D'Amore The role of hypoxia in vascular injury and repair Annu. Rev. Pathol. 3 2008 615 643
34. T.A. Sutton, J. Wilkinson, H.E. Mang, N.L. Knipe, Z. Plotkin, M. Hosein, K. Zak, J. Wittenborn, and P.C. Dagher P53 regulates renal expression of HIF-1alpha and pVHL under physiological conditions and after ischemia-reperfusion injury Am. J. Physiol. Renal Physiol. 295 2008 F1666 F1677
35. M.V. Blagosklonny, W.G. An, L.Y. Romanova, J. Trepel, T. Fojo, and L. Neckers P53 inhibits hypoxia-inducible factor-stimulated transcription J. Biol. Chem. 273 1998 11995 11998
36. W.G. An, M. Kanekal, M.C. Simon, E. Maltepe, M.V. Blagosklonny, and L.M. Neckers Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha Nature 392 1998 405 408
37. R. Gozzelino, V. Jeney, and M.P. Soares Mechanisms of cell protection by heme oxygenase-1 Annu. Rev. Pharmacol. Toxicol. 50 2010 323 354
38. K. Fahmy, C.H. Gray, and D.C. Nicholson The reduction of bile pigments by faecal and intestinal bacteria Biochim. Biophys. Acta 264 1972 85 97
39. K. Tarao, K. Fukushima, S. Otagiri, Y. Saito, and K. Ohara Study on the intestinal bacterial flora, especially its bilirubin metabolism J. Gastroenterol. 6 1971 98
40. L. Vítek, F. Majer, L. Muchová, J. Zelenka, A. Jirásková, P. Branný, J. Malina, and K. Ubik Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833 2006 149 157